Cytokine adsorption in severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation

Organizational Data

DRKS-ID:
DRKS00021300
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2020-04-08
Last update in DRKS:
2021-04-28
Registration type:
Retrospective

Acronym/abbreviation of the study

CYCOV

URL of the study

No Entry

Brief summary in lay language

The primary goal is to investigate the efficacy of treatment with a CytoSorb® cytokine adsorber in patients with severe COVID-19 disease requiring venous ECMO over 72 hours after initiation of ECMO.

Brief summary in scientific language

The primary goal is to investigate the efficacy of treatment with a CytoSorb® adsorber in patients with severe COVID-19 disease who require venous ECMO over 72 hours after initiation of ECMO. The primary endpoint is the reduction of interleukin-6 72 hours after initiation of ECMO support. Secondary endpoints include 30-day survival, vasopressor and volume requirements, and lactate.

Health condition or problem studied

Free text:
SARS-CoV-2-infection (COVID-19-disease) with severe pneumonia
ICD10:
U07.1 - COVID-19, virus identified
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
V-V ECMO with cytokine adsorption using a CytoSorb adsorbers for 72 hours
Arm 2:
V-V ECMO without cytokine adsorption

Endpoints

Primary outcome:
IL-6 at 72 hours after initiation of V-V ECMO
Secondary outcome:
30d survival, ICU survival, katecholamine dosage, urine output, fluid demand, lactate

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Active control (effective treatment of control group)
Phase:
II-III
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • University medical center Freiburg im Breisgau

Recruitment period and number of participants

Planned study start date:
No Entry
Actual study start date:
2020-03-29
Planned study completion date:
No Entry
Actual Study Completion Date:
2021-01-27
Target Sample Size:
30
Final Sample Size:
34

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
100 Years
Additional Inclusion Criteria:
SARS-CoV-2-infection, vv-ECMO

Exclusion Criteria

pregnancy

Addresses

Primary Sponsor

Address:
Universitätsklinikum Freiburg
Dr., MPH Alexander Supady
Hugstetter Strasse 55
79106 Freiburg
Germany
Telephone:
0761/270-73790
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.uniklinik-freiburg.de
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Universitätsklinikum Freiburg
Dr., MPH Alexander Supady
Hugstetter Str. 55
79106 Freiburg
Germany
Telephone:
0761/270-73790
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.uniklinik-freiburg.de

Contact for Public Queries

Address:
Universitätsklinikum Freiburg
Dr., MPH Alexander Supady
Hugstetter Str. 55
79106 Freiburg
Germany
Telephone:
0761/270-73790
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.uniklinik-freiburg.de

Principal Investigator

Address:
Universitätsklinikum Freiburg
Dr., MPH Alexander Supady
Hugstetter Str. 55
79106 Freiburg
Germany
Telephone:
0761/270-73790
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.uniklinik-freiburg.de

Sources of Monetary or Material Support

Institutional budget, no external funding (budget of sponsor/PI)

Address:
Universitätsklinikum Freiburg
Hugstetter Strasse 55
79106 Freiburg
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.uniklinik-freiburg.de

Ethics Committee

Address Ethics Committee

Address:
Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
Engelberger Str. 21
79106 Freiburg
Germany
Telephone:
+49-761-27072600
Fax:
+49-761-27072630
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2020-03-23
Ethics committee number:
168/20
Vote of the Ethics Committee:
Approved
Date of the vote:
2020-03-27

Further identification numbers

Other primary registry ID:
NCT04324528 - clinicaltrials.gov
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
the study protocol and the statistical analysis plan will be published with the publication of the study results

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
DRKS00021248 - Hauptstudie

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry